NCT07636811
A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 10 words
- Trial sites expanded: 10 → 20 locations
- Notable Eligibility criteria expanded, about 11 words
- Trial sites expanded: 3 → 10 locations
- Study completion date: Jul 23, 2031 to Jul 30, 2031
- Minor Study sites: 2 to 3
- Start date changed from estimate of Aug 31, 2026 to Aug 17, 2026
- Notable Recruitment opened
- Start date: Jul 31, 2026 to Aug 31, 2026
- Site details revised at 2 of 2 sites
- Notable Start date: Jul 1, 2026 to Jul 31, 2026v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Double-Blind Period: Change from baseline in brain amyloid burden measured in centiloids (CLs)
Timeframe: Up to 24 months
Secondary (5)
Double-Blind Period: Change from baseline in APP protein concentration in cerebrospinal fluid (CSF)
Double-Blind Period: Change from baseline in the concentration of amyloid beta proteins in CSF
Double-Blind Period: Change from baseline in the concentration of tau proteins in plasma
Double-Blind Period: Change from baseline on a cognitive scale
Double-blind Period and Open-label Extension (OLE) Period: Frequency of adverse events (AEs)
Arms and interventions
Mivelsiran (Treatment Group A)Experimental
Participants will be administered multiple low doses of mivelsiran.
Mivelsiran (Treatment Group B)Experimental
Participants will be administered multiple high doses of mivelsiran.
Placebo (Treatment Group C)Placebo comparator
Participants will be administered multiple doses of placebo.
Drugs: Mivelsiran, Placebo
Sites
20 sites in 3 countries
United States 13, Spain 6, United Kingdom 1